Lung Cancer Research Review, Issue 21

In this issue:

SABR in stage I NSCLC: long-term follow-up data
Early-stage lung adenocarcinoma mutations
Elderly fare worse vs younger patients on chemoRT for NSCLC
Atezolizumab shows promise in metastatic NSCLC
A simple, generalisable prognostic model for lung cancer
Carboplatin vs 2 doses of cisplatin + gemcitabine in advanced NSCLC
Alectinib vs crizotinib in untreated ALK+ NSCLC
Dabrafenib + trametinib in BRAF V600E-mutant NSCLC
TargomiRs for malignant pleural mesothelioma?
Doxorubicin + lurbinectedin in advanced SCLC

Please login below to download this issue (PDF)